{"id":"https://genegraph.clinicalgenome.org/r/abb22ff3-6792-4390-b7af-15d79bc58d0bv2.0","type":"EvidenceStrengthAssertion","dc:description":"*ITPR1* encodes a calcium channel that releases calcium from the endoplasmic reticulum upon stimulation by inositol 1,4,5-trisphosphate (IP3). *ITPR1* was first reported in relation to both autosomal dominant and recessive Gillespie syndrome (also known as aniridia-cerebellar ataxia-intellectual disability syndrome) in 2016 (Gerber et al., PMID: 27108797; McEntagart et al., PMID: 27108798). Clinical features include aniridia or iris hypoplasia, hypotonia, non-progressive cerebellar ataxia, cerebellar atrophy, and variable intellectual disability. Affected individuals are usually diagnosed within the first year of life. The syndrome is caused by heterozygous dominant-negative missense variants or biallelic truncating variants in *ITPR1* that appear to act as partial rather than full loss-of-function variants (PMID: 27108797). Based on the ClinGen Lumping and Splitting guidance, there are differences in inheritance pattern and molecular mechanism and therefore, the autosomal dominant and recessive forms of Gillespie syndrome were assessed separately. This curation concerns autosomal dominant Gillespie syndrome.\n\nSeven unique heterozygous *ITPR1* variants (6 missense and 1 in-frame deletion) identified in 12 unrelated individuals in four publications (PMIDs: 27108797, 27108798, 28698159, 31340402) are included in this curation. More evidence is available in the literature, but the maximum score for genetic evidence (12 points) has been reached. The variants are often *de novo* but may also be inherited from an affected parent. All the missense or in-frame deletion variants in autosomal dominant Gillespie syndrome reported so far are located in the C-terminal region of ITPR1, mainly in the transmembrane channel domain, and affect a restricted number of residues (PMID: 37964426). The mechanism of pathogenicity appears to be dominant negative (PMIDs: 27108797, 27108798).\n\nMice heterozygous for *Itpr1* null variants exhibit mild coordination deficits (PMID: 11334652), but do not replicate the ataxia or eye phenotype seen in Gillespie syndrome (PMIDs: 8538767, 27108798).\n\nOf note, variants in *ITPR1* have also been implicated in two types of autosomal dominant spinocerebellar ataxia, in which iris development is normal: infantile-onset spinocerebellar ataxia type 29, caused by heterozygous missense variants in *ITPR1*, and adult-onset spinocerebellar ataxia type 15, caused by heterozygous loss-of-function variants. The relationship between *ITPR1* and spinocerebellar ataxia will be curated separately. No obvious genotype-phenotype correlations have been observed for the Gillespie syndrome and spinocerebellar ataxia type 29 variants clustered in the C-terminal domain (PMID: 37964426).\n\nIn summary, there is definitive evidence supporting the relationship between *ITPR1* and autosomal dominant Gillespie syndrome. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This gene-disease pair was originally evaluated by the Intellectual Disability and Autism Gene Curation Expert Panel on November 3, 2021 and classified as Definitive. It was reevaluated on January 23, 2025 (SOP Version 11). Although additional evidence was curated, the classification did not change.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/abb22ff3-6792-4390-b7af-15d79bc58d0b","GCISnapshot":"https://genegraph.clinicalgenome.org/r/a848b265-8aa3-41ee-83cc-9287afe0f9d0","calculatedEvidenceStrength":"Definitive","changes":[{"id":"cg:sopChange"},{"id":"cg:summaryChange"},{"id":"cg:otherTextChange"},{"id":"cg:newEvidence"}],"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/a848b265-8aa3-41ee-83cc-9287afe0f9d0_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10006","date":"2025-04-15T20:06:44.566Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/a848b265-8aa3-41ee-83cc-9287afe0f9d0_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10006","date":"2025-01-23T17:00:00.000Z","role":"Approver"}],"curationReasons":["RecurationErrorAffectingScoreorClassification","RecurationNewEvidence"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a848b265-8aa3-41ee-83cc-9287afe0f9d0_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4a7e075f-0952-4652-9ced-a0ca02b454c1","type":"EvidenceLine","dc:description":"This variant was upgraded 0.5 points for recurrence.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4a7e075f-0952-4652-9ced-a0ca02b454c1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27108798","allele":{"id":"https://genegraph.clinicalgenome.org/r/6038296c-1003-4494-b46f-154afadae5e8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001378452.1(ITPR1):c.7660G>C (p.Gly2554Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10581498"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/7dc16735-a73e-4d0f-9847-c3e202c072d3","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7dc16735-a73e-4d0f-9847-c3e202c072d3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28698159","allele":{"id":"https://genegraph.clinicalgenome.org/r/ffebae59-9e2a-4f56-b8ae-301c06f9847c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001378452.1(ITPR1):c.7772A>T (p.Asn2591Ile)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA351649627"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/3ae436f9-164c-41ba-a685-c00bacea804a","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3ae436f9-164c-41ba-a685-c00bacea804a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27108797","allele":{"id":"https://genegraph.clinicalgenome.org/r/f10f202c-a408-4e96-95a3-1f2ee95333fb","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001378452.1(ITPR1):c.7803T>G (p.Phe2601Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10581496"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/5b606c34-85b2-4738-b106-7d93a46222a5","type":"EvidenceLine","dc:description":"This variant was upgraded 0.5 points for recurrence.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5b606c34-85b2-4738-b106-7d93a46222a5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27108798","allele":{"id":"https://genegraph.clinicalgenome.org/r/6038296c-1003-4494-b46f-154afadae5e8"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/3fe231c0-3a11-4101-b5d2-3bd9ef8915c3","type":"EvidenceLine","dc:description":"This in-frame deletion variant was upgraded 0.5 points for recurrence.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3fe231c0-3a11-4101-b5d2-3bd9ef8915c3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27108798","allele":{"id":"https://genegraph.clinicalgenome.org/r/9340a77c-156d-4be7-bbde-3012841bac15","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001378452.1(ITPR1):c.7831_7833del (p.Lys2611del)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10581495"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/3fe231c0-3a11-4101-b5d2-3bd9ef8915c3_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"When the p.Lys2611del mutant was expressed in the DT40-3KO lymphoma cell line devoid of all three endogenous ITPRs, there was no Ca2+ release in response to trypsine stimulation, indicating that the mutant protein does not form functional Ca2+ release channels. Furthermore, when co-produced with wild-type ITPR1, the p.Lys2563del mutant exerted a negative effect (Gerber et al., 2016, PMID: 27108797).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/d5a4ed6e-f5e5-4208-93c8-ad41ccf42c81","type":"EvidenceLine","dc:description":"This variant was upgraded because it is a recurrently mutated residue. Variant inherited from mother with Gillespie syndrome.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d5a4ed6e-f5e5-4208-93c8-ad41ccf42c81_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27108798","allele":{"id":"https://genegraph.clinicalgenome.org/r/cc5184d1-5ff7-4f60-b22a-4133ad5dd96a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001378452.1(ITPR1):c.6326A>G (p.Glu2109Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10581497"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/9be15e6c-76a7-4d6d-9d9b-27eea9914a11","type":"EvidenceLine","dc:description":"This variant was upgraded 0.5 points because it is a recurrently mutated residue.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9be15e6c-76a7-4d6d-9d9b-27eea9914a11_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27108798","allele":{"id":"https://genegraph.clinicalgenome.org/r/8fd29e26-2934-4b6d-b603-83b9a6bf8e4b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001378452.1(ITPR1):c.6325G>C (p.Glu2109Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA351638302"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/4578bd5f-d722-4505-9c46-37b679178464","type":"EvidenceLine","dc:description":"This variant was upgraded 0.5 points because it is a recurrently mutated residue.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4578bd5f-d722-4505-9c46-37b679178464_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31340402","allele":{"id":"https://genegraph.clinicalgenome.org/r/112df2f8-7492-4869-a6bc-f85d3846011e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001378452.1(ITPR1):c.6325G>A (p.Glu2109Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA351638300"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/0d7ea435-9af3-437e-9004-f4745d40ead7","type":"EvidenceLine","dc:description":"This variant was upgraded 0.5 points for recurrence.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0d7ea435-9af3-437e-9004-f4745d40ead7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27108798","allele":{"id":"https://genegraph.clinicalgenome.org/r/6038296c-1003-4494-b46f-154afadae5e8"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/f0c87fa3-250e-45a4-9028-65c07f490d80","type":"EvidenceLine","dc:description":"This in-frame deletion variant was upgraded 0.5 points for recurrence.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f0c87fa3-250e-45a4-9028-65c07f490d80_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27108798","allele":{"id":"https://genegraph.clinicalgenome.org/r/9340a77c-156d-4be7-bbde-3012841bac15"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/f0c87fa3-250e-45a4-9028-65c07f490d80_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"When the p.Lys2611del mutant was expressed in the DT40-3KO lymphoma cell line devoid of all three endogenous ITPRs, there was no Ca2+ release in response to trypsine stimulation, indicating that the mutant protein does not form functional Ca2+ release channels. Furthermore, when co-produced with wild-type ITPR1, the p.Lys2563del mutant exerted a negative effect (Gerber et al., 2016, PMID: 27108797).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/c5761251-92a7-4f0b-802b-633d60508526","type":"EvidenceLine","dc:description":"This in-frame deletion variant was upgraded 0.5 points for recurrence.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c5761251-92a7-4f0b-802b-633d60508526_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27108797","allele":{"id":"https://genegraph.clinicalgenome.org/r/9340a77c-156d-4be7-bbde-3012841bac15"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/c5761251-92a7-4f0b-802b-633d60508526_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"When the p.Lys2611del mutant was expressed in the DT40-3KO lymphoma cell line devoid of all three endogenous ITPRs, there was no Ca2+ release in response to trypsine stimulation, indicating that the mutant protein does not form functional Ca2+ release channels. Furthermore, when co-produced with wild-type ITPR1, the p.Lys2563del mutant exerted a negative effect.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/8ba55e6d-c4fe-4504-bd47-93b50b48b915","type":"EvidenceLine","dc:description":"This in-frame deletion variant was upgraded 0.5 points for recurrence.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8ba55e6d-c4fe-4504-bd47-93b50b48b915_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27108798","allele":{"id":"https://genegraph.clinicalgenome.org/r/9340a77c-156d-4be7-bbde-3012841bac15"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/8ba55e6d-c4fe-4504-bd47-93b50b48b915_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"When the p.Lys2611del mutant was expressed in the DT40-3KO lymphoma cell line devoid of all three endogenous ITPRs, there was no Ca2+ release in response to trypsine stimulation, indicating that the mutant protein does not form functional Ca2+ release channels. Furthermore, when co-produced with wild-type ITPR1, the p.Lys2563del mutant exerted a negative effect (Gerber et al., 2016, PMID: 27108797).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/a848b265-8aa3-41ee-83cc-9287afe0f9d0_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a848b265-8aa3-41ee-83cc-9287afe0f9d0_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/63a8158b-30ac-42a2-a30f-dc22992c30b9","type":"EvidenceLine","dc:description":"These findings donâ€™t provide evidence to support the gene-disease relationship","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d31f6a77-8ffa-46b4-bfe3-d02c5bc6111d","type":"FunctionalAlteration","dc:description":"Analysis of lymphoblastoid cell lines (LCL) from 2 individuals with the p.Gly2539Arg variant and 3 with the p.Lys2596del variant. Western blot showed a variable level of ITPR1 in control and mutant LCL with no clear difference between the groups. Mutant LCL had a higher proportion of ITPR1-positive cells using immunofluorescence (<20% control LCL were ITPR1-positive vs 30-50% in mutant LCL). The authors state that these findings are consistent with an abnormality in the feedback control of nuclear calcium signaling, but they don't provide any evidence to support this claim.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27108798","rdfs:label":"ITPR1 expression in mutant lymphoblastoid cell lines"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/a848b265-8aa3-41ee-83cc-9287afe0f9d0_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/82e2dbde-1519-4d8d-a3ff-f6f6a320c5c2","type":"EvidenceLine","dc:description":"Coordination deficits were only significant in male or female mice at some rotation speeds and not at others, suggesting that the overall deficits are relatively mild. Non-motor behaviors, including learning and memory, were not assessed.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/18c53eba-bff9-403c-8778-bebd9c7050db","type":"Finding","dc:description":"Heterozygous mice with a null Itpr1 variant (deletion of exon 1), described previously by Matsumoto et al. (1996, PMID: 8538767), had impaired motor coordination in the rotarod test. However, in male mice, the differences were significant only in the stationary rotarod, and at 5 and 10 rpm, but not at 20 rpm. The opposite results were observed in females, where significant deficits were observed only at 20 rpm. No differences between genotypes were observed in spontaneous motor activity, grip strength, the hanging test, or walking pattern.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11334652","rdfs:label":"Itpr1 heterozygous exon 1 deletion mice motor coordination","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/54ae0683-8cf4-4f18-a6ed-65690aca421f","type":"EvidenceLine","dc:description":"This heterozygous null variant in mice did not replicate the ataxia phenotype observed in affected individuals with missense variants. The eye phenotype was not examined.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/14537584-edc6-46a1-94ae-8203d7497034","type":"Finding","dc:description":"Mice homozygous for Itpr1 ablation (deletion of exon 1) have severe epilepsy and ataxia and die either in utero or before weaning. Body mass and overall brain size were reduced. However, heterozygous mice grew normally and had no obvious defects. (Eye phenotype not examined.)","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8538767","rdfs:label":"Itpr1 heterozygous mice with exon 1 deletion","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/961ef556-64eb-4e1b-82e9-6bf1e5321b92","type":"EvidenceLine","dc:description":"This heterozygous null variant in mice did not replicate the eye phenotype observed in affected individuals with missense variants.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2a4d2551-c262-471f-a69a-efa6f2f118cd","type":"Finding","dc:description":"Heterozygous mice with an Itpr1 null variant (frameshift variant in exon 57 of 65) showed no major iris defects. Minor defects in the iris were noted in 2 heterozygous adult mice, but no major anomalies consistent with the phenotype seen in Gillespie syndrome could be detected.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27108798","rdfs:label":"Eye phenotype in Itpr1 heterozygous null mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":0.5}],"evidenceStrength":"Definitive","sequence":10251,"specifiedBy":"GeneValidityCriteria11","strengthScore":12.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/FZOnVeYnizA","type":"GeneValidityProposition","disease":"obo:MONDO_0008795","gene":"hgnc:6180","modeOfInheritance":"obo:HP_0000006"},"version":"2.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_a848b265-8aa3-41ee-83cc-9287afe0f9d0-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}